Qiagen believes the flexibility of the Stat-Dx platform for an evolving reimbursement landscape will set it apart from other similar commercial platforms.
The company expects to be able to offer at least one test commercially by the end of this year or early next, with research now starting on two others.
Following the CE-IVD marking, Bruker launched the two products, the multiplex real-time PCR-based Fungiplex Candida assay and the Micronaut-AM test plate.
An OpenArray panel designed to simultaneously test for 17 viruses and 13 bacteria and protozoa was able to detect pathogens from human blood donor samples with an accuracy of about 95 percent.
The company has aspirations for a combined molecular/immunoassay platform, but plans to go to market with a 22-target real-time PCR-enabled syndromic panel.
An investigation and follow-up analysis concluded that the Trioplex test promoted by the CDC was equally sensitive to an alternative singleplex Zika assay, despite the microbiologist's claims to the contrary.
